Diabetes and weight management

Primary Care Diabetes

Volumn 4, Issue , 2010, Pages S24-S30

  Lau, David C W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Basal insulin; Glycaemic control; Obesity; Type 2 diabetes mellitus; Weight management

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DRUG COMBINATION; DRUG EFFECT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; REVIEW; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OBESITY; WEIGHT GAIN;

MLCS; MLOWN;

EID: 77954927363     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/S1751-9918(10)60006-X     Document Type: Article

References (46)

1. Hossain, P., Kawar, B., El Nahas, M., Obesity and diabetes in the developing world – a growing challenge. N. Engl. J Med. 356 (2007), 213–215.
2. International Diabetes Federation, Diabetes Atlas. www.eatlas.idf.org (accessed 6 July 2009).
3. World Health Organization, Facts about diabetes. http://www.who.int/features/factfiles/diabetes/04_en.html.
4. Colditz, G.A., Willett, W.C., Rotnitzky, A., Manson, J.E., Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122 (1995), 481–486.
5. Carey, V.J., Walters, E.E., Colditz, G.A., et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am. J Epidemiol. 145 (1997), 614–619.
6. Chan, J.M., Rimm, E.B., Colditz, G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17 (1994), 961–969.
7. World Health Organization, Facts about obesity and overweight. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/.
8. Prospective Studies Collaboration Whitlock, G., Lewington, S., et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 373 (2009), 1083–1096.
9. Anderson, J.W., Konz, E.C., Obesity and disease management: effects of weight loss on comorbid conditions. Obes. Res. 9:Suppl. 4 (2001), S326–S334.
10. Yusuf, S., Hawken, S., Ôunpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
11. Oldridge, N.B., Stump, T.E., Nothwehr, F.K., Clark, D.O., Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle-and older-age adults. J. Clin. Epidemiol. 54 (2001), 928–934.
12. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J Med. 329 (1993), 977–986.
13. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J Med. 359 (2008), 1577–1589.
14. Wing, R.R., Marcus, M.D., Epstein, L.H., Salata, R., Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 10 (1987), 563–566.
15. Anderson, J.W., Kendall, C.W., Jenkins, D.J., Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J. Am. Coll. Nutr. 22 (2003), 331–339.
16. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J Med. 346 (2002), 393–403.
17. Tuomilehto, J., Lindstrom, J., Eriksson, J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J Med. 344 (2001), 1343–1350.
18. Knowler, W.C., Fowler, S.E., Hamman, R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374 (2009), 1677–1686.
19. Lindström, J., Ilanne-Parikka, P., Peltonen, M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006), 1673–1679.
20. Williamson, D.F., Thompson, T.J., Thun, M., et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23 (2000), 1499–1504.
21. Lean, M.E., Powrie, J.K., Anderson, A.S., Garthwaite, P.H., Obesity, weight loss and prognosis in type 2 diabetes. Diabet. Med. 7 (1990), 228–233.
22. Khan, M.A., St Peter, J.V., Breen, G.A., et al. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes. Res. 8 (2000), 43–48.
23. Hensrud, D.D., Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes. Res. 9:Suppl. 4 (2001), S348–S353.
24. Guare, J.C., Wing, R.R., Grant, A., Comparison of obese NIDDM and nondiabetic women: short-and long-term weight loss. Obes. Res. 3 (1995), 329–335.
25. Lau, D.C.W., Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 176 (2007), 1103–1106.
26. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
27. Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R., Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999), 2005–2012.
28. Russell-Jones, D., Khan, R., Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes. Metab. 9 (2007), 799–812.
29. Mitri, J., Hamdy, O., Diabetes medications and body weight. Expert Opin. Drug Saf. 8 (2009), 573–584.
30. Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009), 17–30.
31. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J Diabetes 32:Suppl. 1 (2008), S53–S61.
32. Peyrot, M., Rubin, R.R., Lauritzen, T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005), 2673–2679.
33. Kurtzhals, P., How to achieve a predictable basal insulin?. Diabetes Metab., 31, 2005, 4S25 4S33.
34. Klein, O., Lynge, J., Endahl, L., et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab. 9 (2007), 290–299.
35. Hollander, P., Cooper, J., Bregnh⊘j, J., Pedersen, C.B., A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin. Ther. 30 (2008), 1976–1987.
36. Rosenstock, J., Davies, M., Home, P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008), 408–416.
37. Fajardo Montañana, C., Hernández Herrero, C., Rivas Fernández, M., Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet. Med. 25 (2008), 916–923.
38. Haak, T., Tiengo, A., Draeger, E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes. Metab. 7 (2005), 56–64.
39. Hermansen, K., Davies, M., Derezinski, T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29 (2006), 1269–1274.
40. Philis-Tsimikas, A., Charpentier, G., Clauson, P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 28 (2006), 1569–1581.
41. Rašlová, K., Bogoev, M., Raz, I., et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res. Clin. Pract. 66 (2004), 193–201.
42. Monami, M., Marchionni, N., Mannucci, E., Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 81 (2008), 184–189.
43. Philis-Tsimikas, A., Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Prefer. Adherence 2 (2008), 323–332.
44. Lüddeke, H.J., Sreenan, S., Aczel, S., et al. PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes. Metab. 9 (2007), 428–434.
45. Dornhorst, A., Lüddeke, H.J., Sreenan, S., et al. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study. Int. J Clin. Pract. 62 (2008), 659–665.
46. Hordern, S.V.M., Wright, J.E., Umpleby, A.M., et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 48 (2005), 420–426.